Patient Scenario 2: Second-Line Treatment Options in Clear-Cell RCC

News
Video

Reviewing the case of a case of a 73-year-old man with metastatic clear cell kidney cancer, experts discuss second-line treatment options informed by prior treatment response, patient goals, and adverse event profiles.

Summary:

In the second case presented, a 73-year-old man, DM, was diagnosed with clear cell kidney cancer after presenting with hematuria, loss of appetite, and left upper quadrant discomfort. Following a left total nephrectomy in January 2021 for a 6-cm left kidney mass (stage 3A, grade 3), the patient experienced liver metastases 8 months later. The initiation of ipilimumab and nivolumab, an immunotherapy combination suitable for intermediate or poor-risk renal cell carcinoma (RCC), eventually led to disease progression, necessitating second-line treatment.

In considering second-line treatments for metastatic kidney cancer, the focus shifts to VEGF receptor tyrosine kinase inhibitors (TKIs) and immunotherapies. The recently presented CheckMate 9ER trial revealed cabozantinib’s notable response rate (41%) in the second line after progression on first-line treatment. Other effective second-line options include tivozanib, lenvatinib plus everolimus, axitinib, and nivolumab, with considerations based on patient-specific factors, treatment history, and adverse effect profiles. Factors influencing the choice of second-line treatment involve evaluating the patient’s response to prior therapies, understanding their goals of care, and considering past medical history. Cardiovascular issues, hypertension, chronic kidney disease, or preexisting conditions like pneumonitis impact the selection of appropriate medications. The diverse adverse effect profiles of different treatments are crucial in aligning therapy with patient tolerance and avoiding exacerbation of existing conditions.

Monitoring patients undergoing advanced kidney cancer treatment involves regular clinic visits (every 4 to 6 weeks on average) for blood work assessing kidney and liver function, urine protein levels, and physical assessments to detect and manage potential TKI adverse effects. The frequency of visits may vary based on individual patient response and adverse effect concerns. Imaging, typically through CT scans, occurs every 10 to 12 weeks, with variations based on treatment response. Recognizing signs of disease progression is vital, involving vigilant monitoring for symptoms such as new or increasing pain, systemic symptoms (fevers, weight loss, fatigue), and difficulties in various bodily functions. These indicators prompt timely intervention, potentially necessitating scans ahead of the regular schedule to assess treatment efficacy. The patient-centered approach integrates clinical, physical, and imaging assessments to tailor ongoing treatment strategies and ensure optimal outcomes.

Summary is AI-generated and reviewed by Cancer Network editorial staff.

Recent Videos
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Related Content